Skip to main content
OpenTrials
Completed

NCT Number: NCT00384631

Intravitreal Bevacizumab for Neovascular Glaucoma

Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neovascular Eye Diseases Glaucoma Ocular Hypertension

Age range

10 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Labbafinejad Medical Center

Tehran, Tehran Province, 16666, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of NVG
  • Vision less than 20/200
  • age 10-80 years

Exclusion criteria

  • Uncontrolled Blood Pressure
  • History of thromboembolism
  • Congestive Heart Failure
  • Renal Failure
  • Pregnancy or Lactation
  • Active ocular or periocular infection
  • No light perception

Treatment and study plan

subconjunctival normal saline

Other

0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals

Avastin

Drug

intravitreal injection of avastin 2.5mg repeated twice at monthly intervals

Primary outcomes

  1. Change in intraocular pressure

    Time frame: 6 months

  2. Change in extent of iris neovascularization

    Time frame: 6 months

Secondary outcomes

  1. Best corrected visual acuity

    Time frame: 6 months

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Shahid Beheshti University of Medical Sciences

Other

Registry information

Official study title

Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial

Acronym: IVB NVG

Important dates

Study start
2006
Study completion
2007
First posted
Oct 6, 2006
Registry last updated
Feb 15, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.